Changes in Beneficial Ownership · 4
Aclaris Therapeutics, Inc.
ACRSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06082026_040607.xml
Filing details
- Report period
- 2026-06-04
- Issuer
- Aclaris Therapeutics, Inc.
- Issuer CIK
- 0001557746
- Trading symbol
- ACRS
Reporting owner 1
- Name
- MILANO VINCENT
- Reporting owner CIK
- 0001187159
- Relationship
- Director
- Address
- C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-05 | M · Form 4 | 11,580 | A | [F1] | 28,896 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 4.71 | 2026-06-04 | A · Form 4 | 42,350 | A | 0 | [F2] | 2036-06-03 | Common Stock | 42,350 | 42,350[F3] | D |
| Restricted Stock Units | [F1] | 2026-06-04 | A · Form 4 | 10,987 | A | 0 | [F4] | [F4] | Common Stock | 10,987 | 10,987[F3] | D |
| Restricted Stock Units | [F1] | 2026-06-05 | M · Form 4 | 11,580 | D | 0 | [F5] | [F5] | Common Stock | 11,580 | 0 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
Footnotes
- F1
- Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.↩ 1↩ 2↩ 3
- F2
- The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.↩ 1
- F3
- This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.↩ 1↩ 2
Signature 1
- Signed
- /s/ Matthew Rothman, Attorney-in-Fact
- Date
- 2026-06-08
Company context
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The Company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.